Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17511899 | 0.74 | EGFR (0.47) | EGFRPIK3CDPIK3CA | |
| SCHEMBL17511898 | 0.74 | EGFR (0.47) | EGFRPIK3CDPIK3CA | |
| SCHEMBL3942457 | 0.70 | EGFR (0.35) | EGFR | |
| SCHEMBL18594 | 0.70 | ALDH1A1 (0.44) | — | |
| SCHEMBL16358 | 0.68 | SIGMAR1 (0.31) | — | |
| SCHEMBL1451430 | 0.68 | MAP4K4 (0.34) | — | |
| SCHEMBL5071855 | 0.68 | CYP1A2 (0.50) | — | |
| SCHEMBL28904201 | 0.68 | DYRK1A (0.40) | — | |
| SCHEMBL1260006 | 0.68 | LMNA (0.36) | — | |
| SCHEMBL12471686 | 0.68 | DCPS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | claimed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | claimed |
| WO-2024040497-A1 | ANTIVIRAL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 清华大学 | 2024-02-29 | — | — | WO | claimed |
| CN-113166119-B | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-114957110-A | Antiviral compound and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | claimed |
| EP-3904352-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-11-03 | — | — | EP | claimed |
| CN-113166119-A | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | claimed |
| CN-103339133-B | 2 of alkoxyl replacement, 3-glyoxalidine is [1,2-c] quinazoline also | 拜耳知识产权有限责任公司 | 2016-06-15 | — | — | CN | claimed |
| EP-0944628-B1 | HETERO-BIARYL-PYRIDOQUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | AMERICAN CYANAMID CO (US) | 2002-06-05 | — | — | EP | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| EP-0944628-A1 | HETERO-BIARYL-PYRIDOQUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | American Cyanamid Company (US) | 1999-09-29 | — | — | EP | claimed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| WO-1998023617-A1 | HETERO-BIARYL-PYRIDOQUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0822187-A1 | PYRAZOLE DERIVATIVES AND HERBICIDES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-02-04 | — | — | EP | claimed |
| US-5672504-A | TREATING MIXED EPOXIDE ENANTIOMORPHS WITH MICROORGANISMS TO INCREASE CONCENTRATION OF OPTICALLY PURE S-ENANTIOMORPHS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-30 | — | — | US | claimed |
| CN-1144526-A | Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents | NISSAN CHEMICAL IND LTD (JP) | 1997-03-05 | — | — | CN | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | GPX4, GPX1, ACAT1 | EGFR 4402/4885PIK3CD 4375/4885PIK3CA 4385/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | EGFR 692/4885PIK3CD 2735/4885PIK3CA 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.